This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis
- NCCN Task Force Report: Bone Health in Cancer Care
- Bone-Seeking Radionuclides For Therapy
- Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate
- Targeting of Osseous Sites with {alpha}-Emitting 223Ra: Comparison with the {beta}-Emitter 89Sr in Mice
- Bone Uptake Studies in Rabbits Before and After High-Dose Treatment with 153Sm-EDTMP or 186Re-HEDP
- The Placorhen Study: A Double-Blind, Placebo-Controlled, Randomized Radionuclide Study with 186Re-Etidronate in Hormone-Resistant Prostate Cancer Patients with Painful Bone Metastases
- Significant Antitumor Effect from Bone-seeking, {alpha}-Particle-emitting 223Ra Demonstrated in an Experimental Skeletal Metastases Model
- High-Dose Treatment with 186Re-HEDP or 153Sm-EDTMP Combined with Amifostine in a Rabbit Model
- Therapy of Metastatic Bone Pain
- Skeletal Uptake and Soft-Tissue Retention of 186Re-HEDP and 153Sm-EDTMP in Patients with Metastatic Bone Disease
- Evaluation of Toxicity and Efficacy of 186Re-Hydroxyethylidene Diphosphonate in Patients with Painful Bone Metastases of Prostate or Breast Cancer
- Quantitative Bone Single-Photon Emission Computed Tomography for Prediction of Pain Relief in Metastatic Bone Disease Treated With Rhenium-186 Etidronate
- Rhenium-186-labeled Hydroxyethylidene Diphosphonate Dosimetry and Dosing Guidelines for the Palliation of Skeletal Metastases from Androgen-independent Prostate Cancer